Pacific Biosciences of California, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $78.6M | $93.5M | $90.7M | $92.8M | $60.6M | $28.2M | $26.0M | $33.9M |
| Cost of Revenue | $53.5M | $58.8M | $46.6M | $39.3M | $37.2M | $21.8M | $25.0M | $20.8M |
| Gross Profit | $25.1M | $34.7M | $44.2M | $53.5M | $23.4M | $6.4M | $940.0K | $13.0M |
| Gross Margin | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | 22.8% | 3.6% | 38.5% |
| Operating Expenses | ||||||||
| Research & Development | $62.6M | $65.3M | $67.6M | $60.4M | $48.2M | $45.2M | $47.6M | $76.1M |
| SG&A Expense | $63.5M | $59.1M | $47.8M | $45.2M | $38.0M | $38.7M | $47.7M | $46.7M |
| Operating Income | $-101.0M | $-89.8M | $-71.2M | $-29.1M | $-62.9M | $-77.5M | $-94.3M | $-109.8M |
| Operating Margin | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | -275.2% | -363.1% | -324.1% |
| Interest Expense | $2.4M | $2.9M | $3.2M | $2.9M | $2.8M | $2.5M | $274.0K | $287.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-102.6M | $-92.2M | $-74.4M | $-31.7M | $-66.2M | $-79.3M | $-94.5M | $-109.4M |
| Net Margin | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | -281.4% | -363.6% | -323.0% |
| EPS (Basic) | $-0.76 | $-0.87 | $-0.83 | $-0.42 | $-0.94 | $-1.26 | $-1.69 | $-2.03 |
| EPS (Diluted) | $-0.76 | $-0.87 | $-0.83 | $-0.42 | $-0.94 | $-1.26 | $-1.69 | $-2.03 |
| Shares Outstanding (Basic) | 135.1M | 116.3M | 92.7M | 80.0M | 73.9M | 66.3M | 56.2M | 55.0M |
| Shares Outstanding (Diluted) | 135.1M | 116.3M | 92.7M | 80.0M | 73.9M | 66.3M | 56.2M | 55.0M |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |